测试阿勒姆图祖马布抗药抗体的长期有效性和成本效益,以指导多发性硬化症的治疗:一项建模研究
Timothy Jamieson1, Florian Tomini2, Sharmilee Gnanapavan3
1Health Economic and Policy Research Unit, Wolfson Institute of population Health, Queen Mary University of London, London, UK. t.jamieson@qmul.ac.uk.
概括
在多发性硬化症 (MS) 中检测抗药抗体可以指导治疗,可能改善结果. 这种方法可能会减少复发并减缓疾病的进展,但成本效益因抗体风险和治疗成本而异.
科学领域:
- 免疫学 免疫学 免疫学
- 神经学 神经学
- 卫生经济学 卫生经济学
背景情况:
- 生物疗法对于多发性硬化症 (MS) 是常见的,但抗药抗体会导致治疗失败.
- 开发抗药抗体 (ADA) 需要进行治疗调整,影响患者的治疗结果和医疗成本.
研究的目的:
- 评估对复发性缓解性多样性硬化症患者的阿勒姆图祖马布抗药抗体测试的临床和经济价值.
- 评估ADA测试是否提高了MS患者的治疗效率和成本效益.
主要方法:
- 使用微模拟模型来预测疾病进展,生活质量和成本.
- 来自英国队列研究的数据提供了与阿勒姆图祖马布治疗的ADA发展风险的信息.
- 治疗策略基于英国MS管理指南.
主要成果:
- 阿拉姆图祖马布的ADA测试导致每人复发率减少0.02,增加了0.06个质量调整后寿命年 (QALY).
- 到二次进展性多发性硬化症的时间延长了0.06年.
- 每个获得的QALY的增量成本为47,861英,受疾病修饰疗法 (DMT) 的使用增加的影响.
结论:
- 测试阿勒姆图祖马布的ADA可以通过指导治疗转换来提高MS的临床结果.
- ADA测试的成本效益取决于ADA发展风险,对药物疗效的影响以及DMT成本.
相关概念视频
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...